Clinical Research Directory
Browse clinical research sites, groups, and studies.
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Sponsor: Dizal Pharmaceuticals
Summary
This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.
Official title: A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
230
Start Date
2023-05-15
Completion Date
2027-10-30
Last Updated
2025-08-11
Healthy Volunteers
No
Conditions
Interventions
DZD8586
DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
Locations (5)
Research site
New York, New York, United States
Research site
Albury, New South Wales, Australia
Research site
Ballarat, Victoria, Australia
Research site
Melbourne, Victoria, Australia
Research site
Perth, Western Australia, Australia